CNS: Fenetresurcours: NewsRenderer
Group by:
Date (Most Recent First)
Industry
Subject
Region
Go
Today is July 01, 2024. All times in Eastern Daylight Time.
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
06/01/2024 - 02:25 PM
TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of seven ...
more
»
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
06/01/2024 - 02:20 PM
TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new patient- and physician...
more
»
ADSK Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Autodesk, Inc. - Contact Kessler Topaz Meltzer & Check, LLP
06/01/2024 - 10:01 AM
RADNOR, Pa.--(BUSINESS WIRE)--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States Dist...
more
»
First Ascent Biomedical Presents Findings from Clinical Studies in Pediatric and Adult Cancers Using its AI-Enhanced Functional Precision Medicine Platform at ASCO 2024
06/01/2024 - 10:00 AM
MIAMI--(BUSINESS WIRE)--First Ascent Biomedical announced findings from ongoing clinical studies conducted in partnership with Florida International University, examining the company’s Functional P...
more
»
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
06/01/2024 - 10:00 AM
COPENHAGEN, Denmark & MAINZ, Germany--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and BioNTech SE (Nasdaq: BNTX) today announced initial data from the Phase 2 GCT1046-04 trial (NCT05117242) evaluati...
more
»
"Experience the Luxury of Japanese Tradition and Cuisine" Reservations for the New Inbound Experience Tour in Osaka's Tondabayashi Begin on June 1, 2024!
06/01/2024 - 10:00 AM
OSAKA, Japan--(BUSINESS WIRE)--The city of Tondabayashi in Osaka is excited to announce a new inbound tour by "SABIWabisabi," aimed at revitalizing the local community. This exclusive tour combines...
more
»
Tempus Announces Expansion of Collaboration with AstraZeneca to Leverage Tempus Next to Support Guideline-directed Biomarker Testing in NSCLC
06/01/2024 - 09:30 AM
CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, today announces an expansion of its collaboration with AstraZeneca, which leverages Tempus Next to arm ...
more
»
Postmedia Announces Closing of Previously Announced Transaction with the Klein Group
06/01/2024 - 09:15 AM
TORONTO--(BUSINESS WIRE)--Postmedia Network Inc., a wholly owned subsidiary of Postmedia Network Canada Corp. (“Postmedia” or “the Company”) today announced that it has closed its previously announ...
more
»
オムディアのRANベンダー・レポートでマべニアがトップに輝く
06/01/2024 - 09:15 AM
テキサス州リチャードソン--(BUSINESS WIRE)--(ビジネスワイヤ) -- ネットワークの未来を構築するクラウドネイティブなネットワーク・インフラストラクチャ・プロバイダーであるマべニアは、オムディアによる最新の「市場環境:2024年RANベンダー」(Market Landscape: RAN Vendors 2024)レポートにおいて、「主要なチャレンジャー(Major cha...
more
»
Sally Hansen® and GLAAD Reprise Their Partnership for the 6th Year With a Launch That Celebrates the LGBTQ+ Community
06/01/2024 - 09:00 AM
NEW YORK--(BUSINESS WIRE)--Since 2019, Sally Hansen® has committed to partnering with GLAAD to support Pride and the organization’s mission to accelerate acceptance for the LGBTQ+ community. In the...
more
»
Ankyra Therapeutics Announces Trial in Progress Poster Presentation at 2024 ASCO Meeting and Approval of ANK-101 Phase 1 Protocol Amendment
06/01/2024 - 09:00 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ankyra Therapeutics, a clinical-stage oncology company developing anchored immunotherapies to improve the therapeutic window for immuno-oncology drugs, announced ...
more
»
Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting
06/01/2024 - 08:10 AM
NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, announced that results from...
more
»
Accutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024
06/01/2024 - 08:00 AM
CRANBURY, N.J.--(BUSINESS WIRE)--Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-enabled drug discovery, announced data from an ongoing Phase 1 study o...
more
»
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer
06/01/2024 - 08:00 AM
PRINCETON, N.J.--(BUSINESS WIRE)--KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced....
more
»
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
06/01/2024 - 08:00 AM
OSAKA, Japan & CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and Pfizer (NYSE: PFE) today announced that the German Hodgkin Study Group (GHSG) will present positive resul...
more
»
1
...
893
894
895
896
897
898
899
900
901
902
903
« Previous
Next »
Get Business Wire News on Your Website
Terms of Use
|
© 2024 Business Wire